|
KMID : 1141720190070010025
|
|
폐쇄성폐질환
2019 Volume.7 No. 1 p.25 ~ p.27
|
|
|
VI Debate on the Positioning of ICS as the First Combination Option in Group D of COPD: Con
|
|
Rhee Chin-Kook
|
|
|
Abstract
|
|
|
|
Inhaled corticosteroid (ICS) is an important drug in the treatment of chronic obstructive pulmonary disease (COPD). Blood eosinophil is so far useful biomarker for ICS. However, the predictive value of blood eosinophil for sputum eosinophil is weak. Variability of blood eosinophil level is also problem. ICS can decrease exacerbation in some COPD patients. However, it also can increase risk of pneumonia, tuberculosis, and non-tuberculosis mycobacteria lung disease. Moreover, it was reported that use of ICS was associated with diabetes and fracture. Thus, personalized treatment is needed when prescribing ICS to COPD patients.
|
|
|
KEYWORD
|
|
|
Chronic obstructive pulmonary disease, Inhaled corticosteroid, Pneumonia, Tuberculosis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|